We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+17.65%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.6B
AUM Growth
+$135M
Cap. Flow
-$15.9M
Cap. Flow %
-0.99%
Top 10 Hldgs %
60.85%
Holding
38
New
3
Increased
13
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
ORKA
Oruka Therapeutics
ORKA
+$46.5M
2
ALKS icon
Alkermes
ALKS
+$40.7M
3
NRIX icon
Nurix Therapeutics
NRIX
+$37.4M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$16.5M
5
MRUS
Merus
MRUS
+$7.83M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$45.4M
2
PCVX icon
Vaxcyte
PCVX
+$34.7M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$27.6M
4
COGT icon
Cogent Biosciences
COGT
+$21.4M
5
IMVT icon
Immunovant
IMVT
+$19.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.53%
2 Financials 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$167M 10.46%
3,350,000
+150,000
+5% +$7.83M
VERA icon
2
Vera Therapeutics
VERA
$2.54B
$109M 6.84%
2,475,000
– –
XENE icon
3
Xenon Pharmaceuticals
XENE
$6.32B
$106M 6.64%
2,700,000
-54,266
-2% -$2.19M
PCVX icon
4
Vaxcyte
PCVX
$7.89B
$105M 6.57%
920,000
-385,000
-30% -$34.7M
ELVN icon
5
Enliven Therapeutics
ELVN
$3.78B
$105M 6.54%
4,100,000
+126,755
+3% +$2.94M
NUVL
6
DELISTED
Nuvalent
NUVL
$96.2M 6.01%
940,000
-547,756
-37% -$45.4M
COGT icon
7
Cogent Biosciences
COGT
$6.79B
$81.4M 5.09%
7,539,930
-2,198,070
-23% -$21.4M
ALKS icon
8
Alkermes
ALKS
$8.82B
$81.2M 5.07%
2,900,000
+1,525,000
+111% +$40.7M
SLNO
9
DELISTED
Soleno Therapeutics
SLNO
$63.6M 3.98%
1,260,000
-165,000
-12% -$7.9M
SYRE icon
10
Spyre Therapeutics
SYRE
$8.87B
$58.5M 3.65%
1,988,084
– –
VRDN icon
11
Viridian Therapeutics
VRDN
$2.13B
$58M 3.63%
2,550,124
+22,092
+0.9% +$361K
CLDX icon
12
Celldex Therapeutics
CLDX
$2.77B
$55M 3.44%
1,618,937
+193,937
+14% +$7.39M
DFTX
13
Definium Therapeutics
DFTX
$5.73B
$45.5M 2.84%
8,000,000
+854,112
+12% +$5.94M
CATX icon
14
Perspective Therapeutics
CATX
$332M
$44.7M 2.79%
3,350,000
-1,307,345
-28% -$17.4M
NRIX icon
15
Nurix Therapeutics
NRIX
$2.43B
$37.1M 2.32%
+1,650,000
New +$37.4M
PHVS icon
16
Pharvaris
PHVS
$2.39B
$35.4M 2.21%
1,911,433
+101,258
+6% +$1.85M
KURA icon
17
Kura Oncology
KURA
$922M
$35.2M 2.2%
1,800,000
+206,650
+13% +$4.19M
RYTM icon
18
Rhythm Pharmaceuticals
RYTM
$7B
$34.1M 2.13%
650,000
-575,000
-47% -$27.6M
ORKA
19
Oruka Therapeutics
ORKA
$5.56B
$33.6M 2.1%
1,369,714
+1,335,187
+3,867% +$46.5M
ARVN icon
20
Arvinas
ARVN
$518M
$29.6M 1.85%
1,200,000
-684,361
-36% -$17.9M
CELC icon
21
Celcuity
CELC
$4.03B
$22.7M 1.42%
1,522,332
+58,227
+4% +$960K
CNTA
22
DELISTED
Centessa Pharmaceuticals
CNTA
$21.6M 1.35%
+1,350,000
New +$16.5M
NKTX icon
23
Nkarta
NKTX
$162M
$21.1M 1.32%
4,662,073
+511,039
+12% +$2.9M
ORIC icon
24
Oric Pharmaceuticals
ORIC
$1.25B
$20.5M 1.28%
2,000,000
– –
CCCC icon
25
C4 Therapeutics
CCCC
$376M
$19.4M 1.21%
3,410,384
– –
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Commodore Capital held 38 positions worth $1.6B, up 9.2% from $1.47B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Commodore Capital's Q3 2024 filing shows 3 new, 13 increased, 9 reduced and 2 closed positions. Its largest new stake was Nurix Therapeutics: 1,650,000 shares worth $37.1M. The largest sale was Nuvalent, an estimated $45.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

  • Commodore Capital's largest Q3 2024 buy was Nurix Therapeutics: 1,650,000 shares worth $37.1M.
  • Commodore Capital added most to Oruka Therapeutics in Q3 2024, an estimated $46.5M increase.
  • Commodore Capital's biggest Q3 2024 reduction was Nuvalent, cutting an estimated $45.4M.
  • Commodore Capital fully exited Immunovant in Q3 2024, selling an estimated $19.8M.
  • Commodore Capital's ten largest holdings make up 61% of its $1.6B portfolio in Q3 2024.
  • Commodore Capital opened 3 new positions and closed 2 in Q3 2024.
  • Commodore Capital's portfolio value rose 9.2% quarter-over-quarter to $1.6B.

Based on Commodore Capital's 13F filing for Q3 2024, filed 14 Nov 2024.